Christopher James Frankenfield insider trades
Open-market stock purchases and sales by Christopher James Frankenfield, Chief Financial Officer at Xilio Therapeutics, Inc, from SEC Form 4 filings since Aug 3, 2023.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jan 2, 2026 | XLO Xilio Therapeutics, Inc | Sold | $4.5K |
| Jan 1, 2026 | XLO Xilio Therapeutics, Inc | Bought (not open market) | — |
| Dec 31, 2025 | XLO Xilio Therapeutics, Inc | Bought (not open market) | — |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Sold (not open market) | $570K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Bought (not open market) | $67.5K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Sold (not open market) | $42.6K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Bought (not open market) | $30K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Sold (not open market) | $315K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Bought (not open market) | $176K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Sold (not open market) | $413K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Bought (not open market) | $225K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Sold (not open market) | $836K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Bought (not open market) | $450K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Bought (not open market) | — |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Sold (not open market) | $1M |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Sold (not open market) | $233K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Sold (not open market) | $158K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Bought (not open market) | $35.7K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Sold (not open market) | $597K |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc | Bought (not open market) | $55.9K |
Companies traded
- XLO Xilio Therapeutics, Inc: 2 sales, last Jan 2, 2026
Get free alerts when Christopher James Frankenfield files a new trade →